Valuation: Bicycle Therapeutics plc

Market Cap 253M 227M 207M 189M 357M 23.79B 368M 2.5B 997M 12.69B 950M 929M 40.07B P/E 2026 *
-1.59x
P/E 2027 * -1.53x
Enterprise Value -260M -233M -213M -194M -366M -24.42B -378M -2.57B -1.02B -13.03B -975M -954M -41.13B EV / Sales 2026 *
-6.81x
EV / Sales 2027 * -20.4x
Free-Float
71.15%
Yield 2026 *
-
Yield 2027 * -
1 day+3.74%
1 week-1.37%
Current month-1.37%
1 month-4.75%
3 months-9.07%
6 months-29.90%
Current year-49.01%
1 week 3.46
Extreme 3.465
3.8
1 month 3.41
Extreme 3.41
4.14
Current year 3.33
Extreme 3.3301
7.34
1 year 3.33
Extreme 3.3301
7.83
3 years 3.33
Extreme 3.3301
28.67
5 years 3.33
Extreme 3.3301
62.08
10 years 3.33
Extreme 3.3301
62.08
Manager TitleAgeSince
Chief Executive Officer 57 2015-08-31
Director of Finance/CFO 46 2026-01-28
Chief Tech/Sci/R&D Officer - 2025-05-31
Director TitleAgeSince
Director/Board Member 57 2015-08-31
Director/Board Member 63 2021-03-16
Director/Board Member 69 2024-02-19
Date Insider Type Main position Quantity % Market Cap. Importance
10/5/26 Sell

Chief Operating Officer

-356 0.0009%
10/5/26 Sell

Chief Operating Officer

-406 0.0011%
10/5/26 Sell

Chief Financial Officer

-79 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
+3.74%-1.37%-44.55%-75.43% 244M
-4.83%+3.51%+53.62%+61.75% 69.4B
+0.02%+1.07%+10.63%+76.66% 57.24B
-1.34%+2.98%+24.79%+100.18% 57.62B
+2.62%+1.68%+28.91%+37.01% 43.65B
+5.09%+9.89%+22.45%+107.48% 44.03B
+8.24%+0.51%+213.26%+792.66% 38.08B
-1.86%+10.13%+26.82%+53.22% 36.31B
-2.97%-6.89%+91.79%+74.60% 32.61B
-2.18%+5.68%+36.21%-0.69% 25.47B
Average +0.65%+3.66%+46.39%+122.75% 40.47B
Weighted average by Cap. +0.05%+4.26%+51.92%+136.67%

Financials

2026 *2027 *
Net sales 38.15M 34.22M 31.27M 28.55M 53.78M 3.59B 55.48M 377M 150M 1.91B 143M 140M 6.04B 7.37M 6.61M 6.04M 5.52M 10.39M 693M 10.72M 72.85M 29.05M 370M 27.67M 27.08M 1.17B
Net income -158M -142M -130M -119M -223M -14.89B -230M -1.57B -624M -7.95B -595M -582M -25.08B -174M -156M -142M -130M -245M -16.33B -253M -1.72B -684M -8.71B -652M -638M -27.51B
Net Debt -513M -460M -420M -384M -723M -48.2B -746M -5.07B -2.02B -25.72B -1.92B -1.88B -81.2B -403M -362M -331M -302M -569M -37.92B -587M -3.99B -1.59B -20.23B -1.51B -1.48B -63.87B
Projected Income Statement - Annual - Bicycle Therapeutics plc
Logo Bicycle Therapeutics plc
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Employees
288
Date Price Change Volume
26-11-06 US$3.610 +3.74% 235,651
26-11-05 US$3.480 -6.45% 499,741
26-11-04 US$3.720 +1.36% 215,100
26-11-03 US$3.670 +1.38% 81,554
26-11-02 US$3.620 -1.09% 348,235
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Bicycle Therapeutics plc
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
3.610USD
Average target price
9.167USD
Spread / Average Target
+153.92%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Bicycle Therapeutics plc
  1. Stock Market
  2. Stocks
  3. BCYC Stock